YieldMax AI & Tech Portfolio Option Income ETF vs Heron Therapeutics Inc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $42.64 (market cap $135.69M), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: YieldMax AI & Tech Portfolio Option Income ETF is the larger of the two by market cap, and YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| GPTY | HRTX | |
|---|---|---|
Market Cap | $135.69M | $68.01M |
Volume | 97,442 | 1,891,941 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $1.49 |
52-Week Low | $34.73 | $0.27 |
Typical Hold Time | — | 35 Days |
Enterprise Value | — | $174.75M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →